In conclusion, we have shown that RAF265, an orally available RAF/VEGFR‐2 inhibitor, produces clinical and metabolic responses in a subset of patients with locally advanced or metastatic melanoma, including patients with BRAF‐WT disease. The gene discussed is RAF1; the disease is metastatic melanoma.